Amneal (AMRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
https://www.zacks.com/stock/news/2267871/amneal-amrx-q1-earnings-how-key-metrics-compare-to-wall-street-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2267871
May 03, 2024 - Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
0
Bausch (BHC) Starts Litigation Against Amneal for Xifaxan
https://www.zacks.com/stock/news/2252178/bausch-bhc-starts-litigation-against-amneal-for-xifaxan?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252178
Apr 08, 2024 - Bausch (BHC) initiates litigation against Amneal Pharmaceuticals and its subsidiaries over a generic version of its lead drug Xifaxan.
0
Amneal (AMRX) Reports Q4 Earnings: What Key Metrics Have to Say
https://www.zacks.com/stock/news/2234560/amneal-amrx-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2234560
Mar 01, 2024 - The headline numbers for Amneal (AMRX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Pages: 1
Page 1